Literature DB >> 11105661

Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action.

J D Jentsch1, R H Roth, J R Taylor.   

Abstract

We have discussed the role of dopamine in modulating the interactions between cortical and striatal regions that are involved in behavioral regulation. The evidence reviewed seems to suggest that dopamine acts, overall, to promote stimulus-induced responding for conditioned or reward-related stimuli by integrative actions at multiple forebrain sites. It is thus not surprising that dopaminergic dysfunction has been implicated in a number of neuropsychiatric disorders that involve abnormal cognitive and affective function. Future studies aimed at pinpointing the precise anatomical sites of action and molecular mechanisms involved in dopaminergic transmission within the corticolimbic circuit are critical for trying to disentangle the cellular mechanisms by which dopamine exerts its actions. Moreover, the afferent control of dopamine neurons from brainstem and forebrain sites need to be fully explored in order to begin to understand what mechanisms are involved in regulating the dopaminergic response to stimuli with incentive value. Finally, the post-synaptic consequences of prolonged and supranormal dopaminergic activation need to be investigated in order to understand what persistent neuroadaptations result from chronic activation of this neuromodulatory system (e.g. in drug addiction). Answers to these sorts of questions will undoubtedly provide important insights into the nature of dopaminergic function in the animal and human brain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11105661     DOI: 10.1016/S0079-6123(00)26028-7

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  29 in total

Review 1.  Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability.

Authors:  R Andrew Chambers; Jane R Taylor; Marc N Potenza
Journal:  Am J Psychiatry       Date:  2003-06       Impact factor: 18.112

2.  Parental education predicts corticostriatal functionality in adulthood.

Authors:  Peter J Gianaros; Stephen B Manuck; Lei K Sheu; Dora C H Kuan; Elizabeth Votruba-Drzal; Anna E Craig; Ahmad R Hariri
Journal:  Cereb Cortex       Date:  2010-09-01       Impact factor: 5.357

Review 3.  Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective.

Authors:  Antonio Alcaro; Robert Huber; Jaak Panksepp
Journal:  Brain Res Rev       Date:  2007-08-21

Review 4.  Neurobiological processes in adolescent addictive disorders.

Authors:  Ty S Schepis; Bryon Adinoff; Uma Rao
Journal:  Am J Addict       Date:  2008 Jan-Feb

5.  An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses.

Authors:  A Carlo Altamura; Marta Serati; Alessandra Albano; Riccardo A Paoli; Ira D Glick; Bernardo Dell'Osso
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-02-18       Impact factor: 5.270

6.  Loss of asymmetric spine synapses in dorsolateral prefrontal cortex of cognitively impaired phencyclidine-treated monkeys.

Authors:  John D Elsworth; Tibor Hajszan; Csaba Leranth; Robert H Roth
Journal:  Int J Neuropsychopharmacol       Date:  2011-06-27       Impact factor: 5.176

7.  Conserved dorsal-ventral gradient of dopamine release and uptake rate in mice, rats and rhesus macaques.

Authors:  Erin S Calipari; Kimberly N Huggins; Tiffany A Mathews; Sara R Jones
Journal:  Neurochem Int       Date:  2012-07-20       Impact factor: 3.921

Review 8.  Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.

Authors:  Sean S O'Sullivan; Andrew H Evans; Andrew J Lees
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

9.  A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia.

Authors:  Holly Moore; J David Jentsch; Mehdi Ghajarnia; Mark A Geyer; Anthony A Grace
Journal:  Biol Psychiatry       Date:  2006-04-11       Impact factor: 13.382

10.  Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.

Authors:  William V Bobo; Richard C Shelton
Journal:  Neuropsychiatr Dis Treat       Date:  2009-07-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.